Star-studded AI biotech launch

DOI: https://doi.org/10.1038/s41587-024-02263-7
IF: 46.9
2024-05-19
Nature Biotechnology
Abstract:The latest biotech aiming to use AI to accelerate drug discovery emerged from stealth on 23 April flush with over $1 billion in venture capital. San Francisco–based Xaira Therapeutics envisions an end-to-end application of AI technologies, from applying fundamental computational methods for biological discovery, to de novo antibody generation, to managing human trials. The foundational technologies, AI-based models for protein and antibody design called RFdiffusion and RFantibody, were developed in the lab of co-founder David Baker at the University of Washington's Institute of Protein Design. Several Baker lab researchers have joined the company full time, as have teams from Illumina and Interline Therapeutics. Xaira's other co-founders include lead investors Bob Nelsen of Arch Venture Partners and Vik Bajaj at Foresite Labs, an incubator affiliated with Foresite Capital. Marc Tessier-Lavigne, former CSO at Genentech and former president of Rockefeller and Stanford Universities, has been named CEO. "Witnessing how AI is impacting other industries and the considerable progress in applications of AI in biology, I believe we are poised for a revolution," said Tessier-Lavigne in a statement. "Xaira is in a strong position to both advance fundamental AI research and translate these advances into transformative new medicines, and I am excited to have the opportunity to lead the team." The company's high-powered board includes Nobel laureate Carolyn Bertozzi, former US Food and Drug Administration commissioner Scott Gottlieb and former Johnson & Johnson chairman and CEO Alex Gorsky.
biotechnology & applied microbiology
What problem does this paper attempt to address?